Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study

Oncotarget. 2016 Jul 12;7(28):43974-43988. doi: 10.18632/oncotarget.9949.

Abstract

Along with molecular abnormalities (mutations in JAK2, Calreticulin (CALR) and MPL genes), chronic inflammation is the major hallmark of Myelofibrosis (MF). Here, we investigated the in vitro effects of crucial factors of the inflammatory microenvironment (Interleukin (IL)-1β, Tumor Necrosis Factor (TNF)-α, Tissue Inhibitor of Metalloproteinases (TIMP)-1 and ATP) on the functional behaviour of MF-derived circulating CD34+ cells.We found that, regardless mutation status, IL-1β or TNF-α increases the survival of MF-derived CD34+ cells. In addition, along with stimulation of cell cycle progression to the S-phase, IL-1β or TNF-α ± TIMP-1 significantly stimulate(s) the in vitro clonogenic ability of CD34+ cells from JAK2V617 mutated patients. Whereas in the JAK2V617F mutated group, the addition of IL-1β or TNF-α + TIMP-1 decreased the erythroid compartment of the CALR mutated patients. Megakaryocyte progenitors were stimulated by IL-1β (JAK2V617F mutated patients only) and inhibited by TNF-α. IL-1β + TNF-α + C-X-C motif chemokine 12 (CXCL12) ± TIMP-1 highly stimulates the in vitro migration of MF-derived CD34+ cells. Interestingly, after migration toward IL-1β + TNF-α + CXCL12 ± TIMP-1, CD34+ cells from JAK2V617F mutated patients show increased clonogenic ability.Here we demonstrate that the interplay of these inflammatory factors promotes and selects the circulating MF-derived CD34+ cells with higher proliferative activity, clonogenic potential and migration ability. Targeting these micro-environmental interactions may be a clinically relevant approach.

Keywords: circulating CD34+ cells; inflammatory microenvironment; migration; myelofibrosis; survival.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, CD34 / blood
  • Antigens, CD34 / metabolism
  • Cell Survival / drug effects
  • Clone Cells / drug effects
  • Clone Cells / metabolism
  • Female
  • Hematopoietic Stem Cells / drug effects*
  • Hematopoietic Stem Cells / metabolism
  • Humans
  • Interleukin-1beta / blood
  • Interleukin-1beta / pharmacology*
  • Male
  • Middle Aged
  • Primary Myelofibrosis / blood
  • Primary Myelofibrosis / metabolism*
  • Primary Myelofibrosis / pathology
  • Tissue Inhibitor of Metalloproteinase-1 / blood
  • Tissue Inhibitor of Metalloproteinase-1 / pharmacology*
  • Tumor Necrosis Factor-alpha / blood
  • Tumor Necrosis Factor-alpha / pharmacology*

Substances

  • Antigens, CD34
  • Interleukin-1beta
  • TIMP1 protein, human
  • Tissue Inhibitor of Metalloproteinase-1
  • Tumor Necrosis Factor-alpha